Pfizer announced on Tuesday that it has enough promising data on its respiratory syncytial virus, or RSV, vaccine designed to protect newborns that it will end enrollment in the study and submit for US Food and Drug Administration approval by the end of the year.

The candidate, RSVpreF, is 81.8% effective at protecting babies from severe cases of the respiratory illness in their first three months of life, and 69.4% effective for six months.

The company plans to file regulatory paperwork in the US by the end of 2022. With FDA approval, this new vaccine could be available to pregnant women next year.

Read the full article here.